Patritumab deruxtecan

Phase 2Withdrawn

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Brain Metastases, Adult

Conditions

Brain Metastases, Adult

Trial Timeline

Jul 1, 2025 → Apr 1, 2027

NCT ID

NCT05620914

About Patritumab deruxtecan

Patritumab deruxtecan is a phase 2 stage product being developed by Daiichi Sankyo for Brain Metastases, Adult. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT05620914. Target conditions include Brain Metastases, Adult.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (6)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05620914	Phase 2	Withdrawn	Jul 1, 2025	Apr 1, 2027	Brain Metastases, Adult
NCT06941272	Phase 1/2	Recruiting	May 26, 2025	Dec 30, 2030	Malignant Neoplasm
NCT06596694	Phase 1/2	Recruiting	Nov 3, 2024	Dec 7, 2028	Gastrointestinal Cancer
NCT05865990	Phase 2	Active	Nov 24, 2023	Oct 1, 2026	Metastatic Breast Cancer
NCT04479436	Phase 2	Terminated	Sep 14, 2020	Feb 3, 2022	Metastatic Colorectal Cancer
NCT02980341	Phase 1/2	Completed	Nov 28, 2016	Sep 7, 2023	Metastatic Breast Cancer

Competing Products

20 competing products in Brain Metastases, Adult

See all competitors

Product	Company	Stage	Hype Score
Abemaciclib + Endocrine therapy	Eli Lilly	Phase 1/2	41
Duloxetine + Sugar pill	Eli Lilly	Phase 2	52
Neurosteroid enantiomer	Oragenics	Phase 2	44
filgrastim + exatecan mesylate	Daiichi Sankyo	Phase 1	33
Eribulin Mesylate	Eisai	Phase 1	33
Pembrolizumab + Lenvatinib	Eisai	Phase 2	52
Palonosetron (Aloxi) and Dexamethasone	Eisai	Phase 2	52
GLIADEL	Eisai	Phase 2	52
Nivolumab + Temozolomide	Ono Pharmaceutical	Phase 3	77
Nivolumab + Temozolomide	Ono Pharmaceutical	Phase 3	77
Prexasertib + Cyclophosphamide + Gemcitabine + filgrastim + peg-filgrastim	Eli Lilly	Phase 1	33
abemaciclib + abemaciclib	Eli Lilly	Phase 2	52
JNJ-17299425	Johnson & Johnson	Phase 2	52
ABT-888	AbbVie	Phase 1	33
Veliparib + Placebo	AbbVie	Phase 2	52
Iressa (Gefitinib)	AstraZeneca	Phase 2	52
Trastuzumab deruxtecan	AstraZeneca	Phase 2	52
Exenatide	AstraZeneca	Approved	85
AZD5213	AstraZeneca	Phase 1	33
Vorinostat	Merck	Phase 1	33

Other Products from Daiichi Sankyo

Olmesartan medoxomil + Olmesartan medoxomil/hydrochlorothiazide + HydrochlorothiazideApproved

OAC aloneApproved

olmesartan medoxomil + Placebo + losartan potassiumApproved

Prasugrel + ClopidogrelApproved

Diet+pravastatinApproved